LGALS3 and breast cancer: Recently, Zhang et al. (2023) reported a label- and amplification-free detection platform, using an engineered nanopore of the bacterial virus phi29 DNA-packaging motor with biomarker galectin 3 (GAL3) and the Thomsen–Friedenreich (TF) binding peptide, to detect basal levels of these biomarkers from nipple aspirate fluid (NAF) samples from BC patients at the single-molecule level [77].